European Journal of Biomedical and Pharmaceutical Sciences

COMPARATIVE STUDY ON AVAILABLE TREATMENT OPTIONS WITH T-AYU-HM PREMIUM FOR SICKLE CELL ANAEMIA: A REVIEW

Urjit Patel*, Nikita Champaneri, Hemshree Desai, Rutvij Desai and Chirag Desai

ABSTRACT

Sickle cell anaemia is a haemoglobin disorder prevailing in countries like India, the USA, and Africa extensively with complex clinical presentation. Sickle cell anaemia is a haemoglobin disorder where every researcher is trying their best to find an ultimate solution for the patients. Several factors were identified contributing to inducing hemolysis and chronic organ damage. The present problem is to increase patient quality of life prospects with low toxicity, safer, and simpler therapies because it mostly affects tribal populations that belong to lower socioeconomic classes and lack access to healthcare and educational facilities. Understanding pathophysiology is important for developing newer therapeutic strategies. In this study, we've covered nutritional supplementation, haemoglobin modulator, red cell rehydration, membrane stabilizer, antioxidant therapy, anti-sickling, and formulation targeting on the adhesion pathway. We tried to highlight little information about existing such therapy in sickle cell anaemia. We aim to compare and analyze the safety and efficacy of the existing traditional system of medicine against modern medicine in the management of sickle cell anaemia.

Keywords: .